News >

Pivotal Denosumab Data Published Highlighting Efficacy in Myeloma

Jason Harris
Published: Tuesday, Feb 13, 2018

Noopur Raje, MD

Noopur Raje, MD
Denosumab (Xgeva) was noninferior to zoledronic acid (Zometa) in preventing skeletal-related event (SREs) in patients with newly diagnosed multiple myeloma, results recently published in The Lancet Oncology.1

In the international, double-blind randomized phase III 482 Study, the RANK ligand inhibitor denosumab was equal to zoledronic acid in delaying time to first SRE (hazard ratio [HR], 0.98; 95% CI, 0.85-1.14; P for noninferiority = .010). Based on these findings, the FDA approved denosumab in January 2018 for the prevention of SREs in patients with multiple myeloma.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication